These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14521487)

  • 1. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension.
    Costagliola C; Parmeggiani F; Sebastiani A
    Expert Opin Pharmacother; 2003 Oct; 4(10):1775-88. PubMed ID: 14521487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
    Zhang WY; Po AL; Dua HS; Azuara-Blanco A
    Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
    Watson P; Stjernschantz J
    Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
    Alm A; Stjernschantz J
    Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study.
    Emmerich KH
    Graefes Arch Clin Exp Ophthalmol; 2000 Jan; 238(1):19-23. PubMed ID: 10664047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
    Camras CB
    Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.
    Stewart WC; Leech J; Sharpe ED; Kulze J; Ellyn J; Day DG
    Am J Manag Care; 2002 Aug; 8(10 Suppl):S240-8. PubMed ID: 12188166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
    Camras CB; Alm A; Watson P; Stjernschantz J
    Ophthalmology; 1996 Nov; 103(11):1916-24. PubMed ID: 8942890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.